Yesterday, Sebastian James, the Managing Director of Boots, announced he is set to leave his role and transition to a new job in the healthcare sector. His departure comes in the wake of the stalled sale of the British beauty and pharmacy chain. James, who joined Boots in 2018, announced his resignation ten months after Roz Brewer, the former CEO of Walgreens Boots Alliance (WBA), the parent company of Boots, also stepped down.
Reflecting on his tenure, James remarked, “Boots has shaped how people access health and beauty products on the high street, and I am proud to have been part of a business that continues to hold a critical role at the center of the U.K. health and beauty sectors.” He will remain with the company until November, and WBA has already begun the search for his successor.
Ornella Barra, Chief Operating Officer, International, at WBA, praised James’ leadership, noting that his tenure has seen Boots “transform through a steadfast focus on investment, innovation, and growth into the number-one health and beauty destination in the U.K.”
James’ exit follows WBA’s failure to offload the chain of 1,900 stores for the second time in four years. Initially, WBA explored a sale of Boots and its No7 beauty brand in 2021 but ultimately decided against it, citing the macroeconomic environment and concerns about a potential U.S. recession.
Despite buyer interest, no offer adequately reflected the high potential value of Boots and No7 Beauty Company. Notably, a joint offer from India’s Reliance Industries and U.S. private equity investor Apollo Global Management valued Boots at between $5 billion and $6 billion.
WBA attempted another sale or flotation of the business this year but again failed to attract sufficient interest. Sources suggest that James’ departure may also be influenced by WBA’s strategic shift towards focusing on the U.S. healthcare sector, which is more lucrative than the retail sector.
Neil Saunders, Managing Director of GlobalData, noted that WBA, which previously grew through various pharmacy acquisitions, has been consolidating its efforts on the U.S. healthcare sector. “The retail side of the business is simply not an area that Walgreens wants to pursue as a major growth opportunity. The potential sale of Boots, which Walgreens would like to dispose of but is waiting for the right conditions, is a further sign of the retreat from retail,” Saunders said.
